Module 1 (KR) — IND / Application Summary (TILA-278)
📚 Part of the TILA-278 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. Module 1 (KR) — IND / Application Summary (TILA-278)
Why it exists. Region-specific administrative content the agency requires in front of the scientific dossier.
How it is produced here. This is a region-specific administrative document, assembled to the local filing and labeling conventions. Its operational and label content is written to stay consistent with the (simulated) clinical data.
Format & governing standard. —
Module 1 (KR) — IND / Application Summary (TILA-278)
Document ID: M1-KR-IND
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): MFDS
Korea (MFDS) IND / Application Summary — TILA-278
Summary supporting the MFDS submission for TILA-278 in Ulcerative Colitis (moderate-to-severe) (study TILA278-201), aligned to the CTD and MFDS regional requirements. MFDS notification; ICH.
This summary supports an application to the Ministry of Food and Drug Safety (MFDS) for approval of a clinical trial plan (Investigational New Drug application) for TILA-278 in adults with moderate-to-severe ulcerative colitis (UC). TILA-278 is a recombinant humanized immunoglobulin G1 (IgG1) bispecific monoclonal antibody produced in Chinese hamster ovary (CHO) cell culture and administered by subcutaneous (SC) injection. The molecule combines two mechanistically complementary binding activities in a single therapeutic entity: an anti-TL1A (TNFSF15) antagonist arm that neutralizes TL1A signaling to dampen TH1/TH17-driven mucosal inflammation and attenuate the pro-fibrotic cascade, and an interleukin-22 receptor (IL-22R) agonist arm that engages IL-22R on intestinal epithelial cells to promote epithelial regeneration, goblet-cell function, and restoration of the mucosal barrier. The therapeutic hypothesis — simultaneous suppression of the inflammatory drive together with active promotion of mucosal healing — is directly aligned with the contemporary treatment goal in UC of combined clinical and endoscopic remission.
The application is supported by a completed randomized, double-blind, placebo-controlled Phase 2b induction study (TILA278-201) that met its primary endpoint of Week-12 clinical remission with a clear dose-ordered treatment effect and an acceptable safety profile, together with the supporting Quality (Module 3) and Nonclinical (Module 4) packages. The dossier is organized in the ICH Common Technical Document (CTD) format accepted by MFDS; cross-references to the relevant CTD modules are provided in Section 12.
1. Product and Application Particulars
| Item | Description |
|---|---|
| Sponsor | Virtual Biopharma Inc. |
| Investigational product | TILA-278 |
| Modality | Humanized IgG1 bispecific monoclonal antibody (anti-TL1A antagonist × IL-22R agonist) |
| Expression system | CHO cell line, fed-batch cell culture |
| Approximate molecular weight | ~148 kDa |
| Route of administration | Subcutaneous (SC) |
| Presentation | Sterile solution in single-use prefilled syringe / autoinjector |
| Proposed indication | Moderate-to-severe ulcerative colitis |
| Lead clinical protocol | TILA278-201 (Phase 2b induction) |
| Application type | MFDS clinical trial plan approval (IND) |
| Dossier format | ICH CTD (Modules 1–5) |
2. Regulatory Basis for the MFDS Submission
The application is submitted under the Pharmaceutical Affairs Act and the associated MFDS regulations governing approval of clinical trial plans for investigational drugs. The proposed Korean study will be conducted in compliance with Korean Good Clinical Practice (KGCP) and the harmonized principles of ICH E6(R2). MFDS is a member of the International Council for Harmonisation, and this submission is prepared in accordance with the adopted ICH guidelines relevant to a biotechnology-derived product, including ICH Q5A(R2) (viral safety), ICH Q5C (stability of biotechnological products), ICH Q6B (specifications for biotechnological products), and ICH S6(R1) (preclinical safety evaluation of biotechnology-derived pharmaceuticals).
Use of foreign clinical data and ethnic-factor considerations. Study TILA278-201 was conducted outside Korea and constitutes the principal body of prior human experience supporting this application. Acceptance and extrapolation of these foreign data to the Korean population are addressed in accordance with ICH E5(R1) (ethnic factors in the acceptability of foreign clinical data). TILA-278 is a monoclonal antibody whose disposition is governed by target-mediated drug disposition and catabolic clearance rather than by cytochrome-P450 metabolism; the intrinsic and extrinsic ethnic factors most likely to influence a large-molecule biologic are therefore limited. The Sponsor proposes to generate Korean/East Asian exposure, efficacy, and safety data within the planned multi-regional confirmatory program (consistent with ICH E17 for multi-regional clinical trials), which will support the acceptability of the foreign induction data and the eventual Korean marketing application.
Quality/GMP. Manufacture of drug substance and drug product is conducted under current Good Manufacturing Practice. Overseas manufacturing sites are subject to MFDS GMP assessment as part of the regulatory pathway; the corresponding facility and quality information is provided in Module 3 (3.2.A.1 and 3.2.R).
3. Development Rationale and Mechanism of Action
Current advanced therapies for moderate-to-severe UC act predominantly by suppressing inflammation, and a substantial proportion of patients fail to achieve, or lose, response and do not reach the deeper targets of endoscopic and mucosal healing. TILA-278 was designed to address this gap by pairing two independent activities on a single IgG1 scaffold:
- TL1A antagonism (anti-inflammatory / anti-fibrotic). TL1A, acting through DR3, amplifies effector T-cell responses and promotes intestinal fibrosis. Neutralization reduces TH1/TH17-associated cytokine output and attenuates pro-fibrotic signaling.
- IL-22R agonism (epithelial / mucosal healing). Agonism of IL-22R on intestinal epithelium drives epithelial regeneration, antimicrobial-peptide and mucin production, and restitution of the epithelial barrier.
By combining suppression of the inflammatory drive with active promotion of mucosal repair, TILA-278 is intended to produce deeper and more durable disease control than agents acting on inflammation alone. The dose-ordered efficacy observed in TILA278-201 (Section 8) is consistent with this dual mechanism.
4. Quality (Chemistry, Manufacturing, and Controls) Summary
Full quality information is provided in Module 3; cross-references are given in Section 12.
Drug substance. TILA-278 drug substance is a recombinant humanized IgG1 bispecific mAb expressed in a CHO cell line by fed-batch culture. Downstream processing comprises Protein-A affinity capture followed by orthogonal polishing chromatography (cation- and anion-exchange) to control product- and process-related impurities. Viral safety is assured through a combination of raw-material and cell-bank virus testing and dedicated clearance steps (low-pH viral inactivation and viral-retentive nanofiltration) in accordance with ICH Q5A(R2). The drug substance is characterized for identity (peptide mapping; intact and reduced mass by LC-MS; confirmation of correct bispecific pairing/assembly), purity and product-related impurities (aggregates/high-molecular-weight species by SEC with ≤ 2% aggregate; fragments by CE-SDS; charge variants by imaged capillary isoelectric focusing), Fc N-glycan profile, and process/safety-related impurities (host-cell protein, residual DNA, residual Protein A, endotoxin/bioburden), each controlled to phase-appropriate limits per ICH Q6B.
Potency. A dual, arm-specific potency strategy is applied: an anti-TL1A neutralization cell-based assay and an IL-22R agonism reporter/functional assay, each with defined acceptance criteria, ensuring both functional activities are controlled.
Drug product. The drug product is a sterile aqueous solution for SC injection at a nominal concentration of 150 mg/mL, formulated in histidine/histidine-HCl buffer at pH ~5.8 with polysorbate (e.g., polysorbate 80) as surfactant and a stabilizing sugar (e.g., sucrose), presented in a single-use prefilled syringe/autoinjector with biologics-qualified container-closure and elastomeric components. The drug-product release specification includes appearance, protein concentration, pH, osmolality, sub-visible and visible particulates, purity/impurities (SEC, CE-SDS, icIEF), both potency assays, sterility, endotoxin, and container-closure/functional testing appropriate to the device presentation.
Stability. Formal stability studies are conducted under ICH Q1A/Q5C conditions (long-term, accelerated, and stress). The proposed drug-product shelf life is 24 months at 2–8 °C, protect from light, with defined in-use stability for room-temperature equilibration prior to injection.
5. Nonclinical Summary
Full study reports are provided in Module 4; cross-references are given in Section 12. The program was designed in accordance with ICH S6(R1).
TILA-278 binds human TL1A and human IL-22R with high specificity, and both targets are engaged in a strictly human-specific manner; conventional rodent species are therefore not pharmacologically relevant. The cynomolgus monkey is the sole pharmacologically relevant species for both binding arms and was used for repeat-dose SC toxicology, with safety-pharmacology endpoints (cardiovascular including telemetry-based blood pressure, heart rate, and ECG intervals; respiratory; and central-nervous-system parameters) integrated into the general-toxicology studies. Primary pharmacodynamic studies employing species-appropriate surrogate and/or target knock-in approaches confirmed the intended dual mechanism (reduced TH1/TH17 cytokines and pro-fibrotic readouts with TL1A antagonism; enhanced epithelial-regeneration and barrier markers with IL-22R agonism).
Toxicokinetics were consistent with a monoclonal antibody exhibiting target-mediated drug disposition (TMDD) at low exposures and approximately linear kinetics at higher exposures, with a prolonged terminal half-life supporting infrequent SC dosing. Anti-drug antibodies were detected in a subset of animals, as expected for a human antibody administered to a non-human species, without precluding sustained exposure. Tissue cross-reactivity studies on human and cynomolgus tissue panels showed binding consistent with the known distribution of the targets and no unexpected off-target binding. Repeat-dose SC studies identified no adverse target-organ toxicity; findings were limited to expected exaggerated-pharmacology/immune-related changes and injection-site observations that were reversible in recovery, with a NOAEL at the highest dose tested providing multiples over anticipated clinical exposure. Local tolerance at the SC injection site supported the clinical presentation.
Consistent with ICH S6(R1), genotoxicity and carcinogenicity studies are not warranted for a monoclonal antibody of this class and were not conducted. Reproductive and developmental toxicology is addressed in a manner and timing appropriate to the intended population and dosing duration; the available package supports the proposed studies in a non-pregnant adult population with standard contraception requirements.
6. Clinical Pharmacology Summary
The clinical pharmacology of TILA-278 is that of a therapeutic IgG1 bispecific antibody administered subcutaneously:
- Absorption / bioavailability. SC administration is expected to give an absolute bioavailability in the range typical of therapeutic mAbs (approximately 60–70%), with delayed time-to-peak consistent with lymphatic absorption.
- Distribution and elimination. PK are dominated by TMDD, yielding non-linear behavior at lower exposures and approximately linear elimination at higher exposures; the terminal half-life supports every-2-to-4-week SC dosing.
- Exposure–response. The dose-ordered efficacy observed in TILA278-201 supports a positive exposure–response relationship for clinical remission, to be formalized in dedicated population-PK and exposure–response analyses.
- Immunogenicity. Anti-drug antibodies are assessed with a tiered assay strategy (screening → confirmatory → titer, with neutralizing-antibody characterization), and their impact on PK, efficacy, and safety is evaluated.
- Cardiac safety. Consistent with ICH E14/S7B for a large-molecule biologic with no expectation of direct ion-channel (e.g., hERG) interaction, a dedicated thorough QT study is not warranted; cardiac safety is monitored via ECGs within the clinical program and the cynomolgus safety-pharmacology assessment.
7. Summary of Clinical Experience — Protocol TILA278-201
The full protocol and clinical study report are provided in Module 5. This completed induction study constitutes the principal prior human experience supporting the application.
| Field | Description |
|---|---|
| Protocol number | TILA278-201 |
| Title | A Phase 2b, randomized, double-blind, placebo-controlled, parallel-group study of TILA-278 for induction of remission in moderate-to-severe ulcerative colitis |
| Phase | 2b (induction) |
| Investigational product | TILA-278, administered subcutaneously at two dose levels (High and Low) |
| Comparator | Matching placebo, SC |
| Design | Randomized, double-blind, placebo-controlled, parallel-group |
| Randomization | 1:1:1 (TILA-278 High : TILA-278 Low : Placebo) |
| Stratification | Baseline modified Mayo disease severity; prior biologic exposure |
| Treatment duration | 12-week induction |
| Study visits | Weeks 0, 2, 4, 8, and 12 |
| Screened / randomized | 1700 screened; 900 randomized (High 299 / Low 300 / Placebo 301) |
| Full Analysis Set (FAS) | 840 (High 284 / Low 283 / Placebo 273) |
Objectives and endpoints. The primary objective was to evaluate the efficacy of TILA-278 versus placebo for induction of clinical remission at Week 12. The primary endpoint was clinical remission at Week 12, defined as a modified Mayo score ≤ 2 with no individual subscore > 1. Key secondary objectives included change from baseline in modified Mayo score, endoscopic improvement and mucosal healing, symptomatic response, and characterization of safety, tolerability, PK, and immunogenicity.
Population. Eligible subjects were adults (≥ 18 years) with UC diagnosed at least 3 months before screening and moderate-to-severe disease activity (baseline modified Mayo score in the moderate-to-severe range with a centrally read endoscopic subscore ≥ 2) who had demonstrated inadequate response to, loss of response to, or intolerance of conventional therapy (corticosteroids and/or immunomodulators) and/or approved biologic or targeted synthetic agents. Key exclusions included Crohn's disease or indeterminate colitis, prior colectomy or planned colitis-related surgery, and active or serious infection (with tuberculosis screening requirements).
Statistical methods. The primary analysis compared each TILA-278 dose with placebo for Week-12 clinical remission in the FAS. The LS-mean change from baseline in modified Mayo score was analyzed by ANCOVA with treatment and stratification factors and baseline score as covariate. Multiplicity across the two dose comparisons was controlled by a pre-specified testing procedure. Safety was summarized descriptively in the safety population.
8. Efficacy Results
Clinical remission at Week 12 (primary endpoint; FAS). A clear, dose-ordered treatment effect was observed, with both TILA-278 doses superior to placebo.
| Arm | Remission, n/N | Remission rate | Risk difference vs placebo (95% CI) | p-value |
|---|---|---|---|---|
| TILA-278 High | 106/284 | 37.3% | 36.6% (30.9, 42.3) | < 0.0001 |
| TILA-278 Low | 46/283 | 16.2% | 15.5% (11.1, 19.9) | < 0.0001 |
| Placebo | 2/273 | 0.7% | — (reference) | — |
Change from baseline in modified Mayo score at Week 12 (FAS; ANCOVA).
| Arm | LS-mean change | Difference vs placebo (95% CI) | p-value |
|---|---|---|---|
| TILA-278 High | –3.36 | –2.36 (–2.49, –2.23) | < 0.0001 |
| TILA-278 Low | –2.76 | –1.77 (–1.90, –1.64) | < 0.0001 |
| Placebo | –1.00 | — (reference) | — |
Endoscopic improvement at Week 12. Endoscopic improvement was likewise dose-ordered and consistent with the mucosal-healing arm of the mechanism: 48.9% (High), 27.9% (Low), and 6.2% (Placebo).
Both dose comparisons for the primary endpoint were highly statistically significant, and the magnitude of effect, remission rates, and endoscopic improvement were dose-ordered (High > Low > Placebo), supporting a positive exposure–response relationship consistent with the intended dual mechanism.
9. Safety Results
TILA-278 was generally well tolerated over the 12-week induction period. There was no dose-dependent safety signal; the principal drug-attributable finding was injection-site reactions, higher on active SC drug as expected for the SC route.
| Parameter (subjects) | TILA-278 High | TILA-278 Low | Placebo |
|---|---|---|---|
| ≥ 1 TEAE | 109 | 131 | 130 |
| Serious adverse events (SAEs) | 3 | 0 | 4 |
| Deaths | 2 | 0 | 1 |
| Discontinuations | 17 | 17 | 29 |
- Deaths (2 High / 0 Low / 1 Placebo) were all assessed as unrelated to study drug.
- Discontinuations were highest on placebo (29), driven predominantly by lack of efficacy.
- Most frequent adverse events across the study included nasopharyngitis, headache, worsening UC (higher on placebo), anaemia, arthralgia, upper respiratory tract infection, injection-site reaction (higher on active SC drug), and nausea.
Immunogenicity (ADA) was monitored throughout with the tiered assay strategy described in Section 6, with assessment of any impact on PK, efficacy, and safety.
10. Benefit–Risk and Conclusions
TILA278-201 met its primary endpoint, demonstrating statistically significant and clinically meaningful, dose-ordered induction of clinical remission with TILA-278 versus placebo in moderate-to-severe UC (37.3% High and 16.2% Low vs 0.7% placebo), accompanied by concordant benefits on modified Mayo change from baseline and endoscopic improvement. The safety profile over the induction period was favorable and manageable, with injection-site reactions the main drug-attributable finding and no dose-dependent safety signal. The Quality and Nonclinical packages support administration of TILA-278 at the exposures proposed for the Korean program. The overall benefit–risk assessment is favorable and supports the proposed clinical development in Korea.
11. Proposed Korean Clinical Development Plan
The Sponsor proposes to include Korean sites in the confirmatory development of TILA-278 for induction and maintenance of remission in adults with moderate-to-severe UC. Over the period following MFDS clearance, the plan is to: (1) confirm and extend the induction findings in a multi-regional population that includes Korean subjects and both biologic-naïve and biologic-experienced patients, reproducing the TILA278-201 primary endpoint (Week-12 clinical remission by modified Mayo score); (2) characterize a maintenance regimen to establish durability of clinical remission, endoscopic improvement, and mucosal healing; and (3) complete the clinical-pharmacology package (SC bioavailability, exposure–response, and immunogenicity), including generation of Korean/East Asian exposure and response data to support the acceptability of the foreign induction data under ICH E5(R1) and E17. Dose levels will bracket the TILA-278 Low and High levels evaluated in TILA278-201. Material changes to the plan will be submitted to MFDS as amendments to the approved clinical trial plan.
12. Cross-Reference Index (CTD Modules and Regional Documents)
| Content | CTD module / location |
|---|---|
| Application form and cover letter (KR) | Module 1 — M1-KR-FORM |
| Administrative content and Korean label | Module 1 — M1-KR |
| Korea Risk Management Plan | Module 1 — M1-KR-RMP |
| Quality (CMC) — drug substance / drug product | Module 3 (3.2.S, 3.2.P) |
| Quality — appendices and regional (viral safety, facilities, GMP) | Module 3 (3.2.A, 3.2.R) |
| Nonclinical study reports | Module 4 (4.2.1 – 4.2.3) |
| Clinical pharmacology and study data | Module 5 (5.3.1 – 5.3.3) |
| Clinical protocol TILA278-201 | Module 5 (5.3.5.1) |
| Clinical study report TILA278-201 | Module 5 (5.3.5) |
| Investigator's Brochure | Module 1 / Module 5 supportive |
Comments (0)
No comments yet. Be the first to say something!